Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?

Table 2 Patient characteristics at cART resumption after transient cART started during PHI versus cART initiation during CHI

Characteristics^a	ART resumption after transient cART during PHI, N = 136		cART initiation during CHI, N = 377		p value
Age, years	43	(37–50)	40	(34–47)	<0.0001
CD4 cells/mm3 ^b	303	(246–442)	332	(248–426)	0.9
HIV load log ₁₀ copies/mL	4.7	(4.2-5.3)	4.9	(4.4-5.3)	0.7
Time between HIV infection and cART resumption/initiation, months	46	(26–72)	23	(12–42)	<0.0001
Year of cART resumption/initiation	2006	(2003–2010)	2009	(2007–2010)	<0.0001
Duration of cART after resumption/initiation, months	47	(23–66)	32	(18–51)	0.0002
Duration of viral control on cART, months	45	(22–56)	30	(18–49)	0.0007
cART regimen % (n)
Boosted protease inhibitor (PI) or anti- integrase	43	(58)	59	(223)	<0.0001

^aData are medians (IQR) or % (n).
^bBaseline CD4 cell count and HIV load values were obtained between 1 month before cART initiation and 7 days following cART initiation; the number of corresponding CD4 cell counts was N = 77 for patients treated during PHI and N = 234 for patients treated during CHI.

ISSN: 1471-2334